Evidence map›Paper›PMID 42783140›Full record

ReviewBiosensors2026

Microfluidic Single-Cell Bioanalysis for Decoding Tumor Heterogeneity.

Xingyu Tao, Shuang Feng, Yi Luo, Zhenfei Yu, Ruiheng Wang, Ru-Jia Yu

Abstract readReview
In one paragraph

Review in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xingyu TaoState Key Laboratory of Flexible Electronics (LoFE), Institute of Advanced Materials (IAM), Nanjing University of Posts and Telecommunications, Nanjing 210023, China.
Shuang FengState Key Laboratory of Flexible Electronics (LoFE), Institute of Advanced Materials (IAM), Nanjing University of Posts and Telecommunications, Nanjing 210023, China.
Yi LuoState Key Laboratory of Flexible Electronics (LoFE), Institute of Advanced Materials (IAM), Nanjing University of Posts and Telecommunications, Nanjing 210023, China.
Zhenfei YuState Key Laboratory of Flexible Electronics (LoFE), Institute of Advanced Materials (IAM), Nanjing University of Posts and Telecommunications, Nanjing 210023, China.
Ruiheng WangDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA 91010, USA.
Ru-Jia YuState Key Laboratory of Flexible Electronics (LoFE), Institute of Advanced Materials (IAM), Nanjing University of Posts and Telecommunications, Nanjing 210023, China.ORCID 0000-0002-5376-3648

Funding

National Natural Science Foundation of China 22276089
6 · The paper itself

Abstract

Tumor heterogeneity drives cancer progression, dissemination, therapeutic adaptation, and relapse, yet many clinically relevant cell states are rare, transient, context-dependent, and obscured by population-averaged analysis. This review examines how microfluidic platforms preserve biologically meaningful linkages among cell identity, molecular state, secreted output, functional phenotype, perturbation history, and microenvironmental context, which are frequently disrupted by conventional workflows. We first define analytical requirements imposed by tumor heterogeneity, then examine microwell- and microchamber-based systems, droplet microfluidic platforms, valve-assisted and other active manipulation or capture systems, and integrated multimodal workflows that preserve single-cell information while introducing distinct engineering trade-offs. We further discuss major readout modalities, including genomic and transcriptomic profiling, extracellular vesicle and secretome analysis, metabolic measurements, and proteomic readouts, and applications in circulating tumor-cell dissemination, tumor-microenvironment interactions, and therapy-response heterogeneity. Finally, we highlight bottlenecks in measurement fidelity, source attribution, reproducibility, benchmarking, biological representation, multimodal integration, and clinical validation. We propose that microfluidic single-cell oncology should advance from descriptive profiling toward decision-oriented systems that preserve cell-resolved states, source-attributed outputs, perturbation histories, and longitudinal responses within reproducible workflows and connect them to clinically actionable information.

Indexed as

Microfluidic Analytical TechniquesMicrofluidicsNeoplasmsSingle-Cell AnalysisHumansProteomicsTumor Microenvironmentclinical validationextracellular vesiclesmicrofluidic bioanalysissingle-cell analysissource attributiontumor heterogeneity

Identifiers

PMID42783140
PMCPMC13604530

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.